title: Pyroglutamate formation influences solubility and amyloidogenicity of amyloid peptides.
abstract: N-Terminally truncated and pyroglutamate (pGlu) modified amyloid beta (Abeta) peptides are major constituents of amyloid deposits in sporadic and inherited Alzheimer's disease (AD). Formation of pGlu at the N-terminus confers resistance against cleavage by most aminopeptidases, increases toxicity of the peptides, and may seed Abeta aggregate formation. Similarly, the deposited amyloid peptides ABri and ADan, which cause a very similar histopathology in familial British dementia (FBD) and familial Danish dementia (FDD), are N-terminally blocked by pGlu. Triggered by the coincidence of pGlu-modified amyloid peptides and similar pathology in AD, FBD, and FDD, we investigated the impact of N-terminal pGlu on biochemical and biophysical properties of Abeta, ABri, and ADan. N-Terminal pGlu increases the hydrophobicity and changes the pH-dependent solubility profile, rendering the pGlu-modified peptides less soluble in the basic pH range. The pGlu residue increases the aggregation propensity of all amyloid peptides as evidenced by ThT fluorescence assays and dynamic light scattering. The far-UV CD spectroscopic analysis points toward an enhanced beta-sheet structure of the pGlu-Abeta. Importantly, changes in fibril morphology are clearly caused by the N-terminal pGlu, resulting in the formation of short fibers, which are frequently arranged in bundles. The effect of pGlu on the morphology is virtually indistinguishable between ABri, ADan, and Abeta. The data provide evidence for a comparable influence of the pGlu modification on the aggregation process of structurally different amyloid peptides, thus likely contributing to the molecularly distinct neurodegenerative diseases AD, FBD, and FDD. The main driving force for the aggregation is apparently an increase in the hydrophobicity and thus an accelerated seed formation.
authors.affiliation: Probiodrug AG, Weinbergweg 22, 06120 Halle/Saale, Germany.
authors.forename: Dagmar
authors.initials: D
authors.lastname: Schlenzig
authors.forename: Susanne
authors.initials: S
authors.lastname: Manhart
authors.forename: Yeliz
authors.initials: Y
authors.lastname: Cinar
authors.forename: Martin
authors.initials: M
authors.lastname: Kleinschmidt
authors.forename: Gerd
authors.initials: G
authors.lastname: Hause
authors.forename: Dieter
authors.initials: D
authors.lastname: Willbold
authors.forename: Susanne Aileen
authors.initials: SA
authors.lastname: Funke
authors.forename: Stephan
authors.initials: S
authors.lastname: Schilling
authors.forename: Hans-Ulrich
authors.initials: HU
authors.lastname: Demuth
mesh_terms: D000544:Alzheimer Disease / Q000378:metabolism; D000595:Amino Acid Sequence; D000682:Amyloid / Q000737:chemistry / Q000378:metabolism* / Q000648:ultrastructure; D002942:Circular Dichroism; D006801:Humans; D006863:Hydrogen-Ion Concentration; D008854:Microscopy, Electron; D008969:Molecular Sequence Data; D010455:Peptides / Q000737:chemistry / Q000378:metabolism*; D011761:Pyrrolidonecarboxylic Acid / Q000378:metabolism*; D012995:Solubility; D013056:Spectrophotometry, Ultraviolet
chemical_list: D000682:Amyloid; D010455:Peptides; D011761:Pyrrolidonecarboxylic Acid